A Study Evaluating Bilastine Ophthalmic Solution 0.6% in the Conjunctival Allergen Challenge (Ora-CAC®) Model
Status:
Completed
Trial end date:
2018-08-13
Target enrollment:
Participant gender:
Summary
To evaluate the efficacy of Bilastine ophthalmic solution 0.6% compared to vehicle and
Zaditen (Ketotifen ophthalmic solution 0.025%) for the treatment of the signs and symptoms of
allergic conjunctivitis.